ENDO acquisition of Indevus for more than ValstarI think another view of this Valstar thing is that while the drug itself is not a revenue maker. ENDO did gain the access and the market presence into the bladder cancer market through Indevus marketing and sales force. That will bode well for Urocidin. it gives it an immediate market access when it launches. And because of this, it might behooves ENDO to expedite the Urocidin approval process before they lose the market presence in urological field due to the disappointing result of Valstar.
Just another example of looking at the same coin from two sides!